Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
News|Articles|March 5, 2026
- Vol.27/No.5
- Volume 27
- Issue 05
Rising Incidence, Unclear Drivers: Knowledge Gaps Persist in Early-Onset CRC
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Kirsty Mackay
John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.
Advertisement
Advertisement
Colorectal cancer (CRC) incidence among adults younger than 50 years has nearly doubled since the 1990s, transforming what was once a projected trend into a present-day clinical crisis.1 By 2030, CRC is projected to increase in incidence by 90%, and recent data show that the disease is already the leading cause of cancer-related death among men and women younger than 50 years.1,2
Related to this article
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
Advertisement
Advertisement